Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Shares Outstanding (Weighted Average) (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $363.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 13.44% to $363.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $363.1 million through Dec 2025, up 13.44% year-over-year, with the annual reading at $363.1 million for FY2025, 13.44% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $363.1 million at Lexicon Pharmaceuticals, roughly flat from $362.9 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $363.3 million in Q2 2025, with the low at $183824.0 in Q2 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $276.0 million, with a median of $299.1 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 151193.08% in 2024, then rose 0.4% in 2025.
  • Over 3 years, Shares Outstanding (Weighted Average) stood at $221.1 million in 2023, then skyrocketed by 44.73% to $320.0 million in 2024, then increased by 13.44% to $363.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $363.1 million, $362.9 million, and $363.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.